Oncology ABCs (part 2) Webinar – Vaccines: Niche no longer

Oncology ABCs (part 2) Webinar – Vaccines: Niche no longer

As a follow-on to Oncology ABCs (part 2) – Vaccines: Niche no longer, we spoke to two seasoned oncology experts to better understand the innovative technologies, recent trends and momentum in combination therapies. The most notable and recent catalysts are expected to continue to fuel advances and include heightened immunotherapy awareness, momentum in combination therapies (extending survival) and a drive for personalised medicine. We expect these recent trends and overall wider acceptance of complex vaccines to reinvigorate deal activity which targets companies with the most robust and innovative technologies.

Jens Bjørheim, Chief Medical Officer of Ultimovacs
Jeroen Rovers, Chief Medical Officer of Mendus (previously Immunicum)
Soo Romanoff, Managing Director – Healthcare, Head of Content, Edison Group

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free